2022-RA-448-ESGO Venous thromboembolic disease in ovarian cancer: incidence, impact on overall survival and development of a predictive score

Abstract

2022-RA-437-ESGO Figure 2 Forrest plot included studies for the (A) serum healthy versus benign comparison of IL-6 levels; (B) serum healthy versus malignant comparison of IL-6 levels; © serum benign versus malignant ovarian conditions coparison of IL-6 levels; (D) ascites benign versus malignant ovarian conditions comparison of IL-6 levels Conclusion Higher levels of plasma or serum IL-6 in ovarian neoplasia patients compared to benign conditions or healthy controls identify IL-6 as a discerning factor between benign or malignant ovarian tumors and a potential biomarker for ovarian malignancy.